GoodRx Holdings, Inc. Class A GDRX

Amazon.com, Inc. (NASDAQ:AMZN) and GoodRx Holdings, Inc. (NASDAQ:GDRX) are signing up Americans for flat-fee prescription plans as health insurance coverage thins, according to a Reuters report on September 29. Amazon charges from $5 a month and GoodRx from $14.99, with both including a range of generic drugs at no extra cost. GoodRx calls its version […]

Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are usually cheap for a reason, and a low valuation can reflect underlying business challenges rather than a genuine bargain.

Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.

SANTA MONICA, Calif., September 03, 2026--GoodRx (Nasdaq: GDRX), the trusted platform for prescription access and affordability in the U.S., today launched the GoodRx Companion Family Plan, expanding its everyday healthcare subscription to the entire family, including pets. As widening coverage gaps and rising out-of-pocket costs leave households paying more for care, the new plan brings Companion’s free and low-cost prescriptions and savings on common healthcare services together in one afforda

The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, upbeat results, or supportive macro developments. As such, investors are taking notice and bidding up shares.

Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at GoodRx (NASDAQ:GDRX) and its peers.

Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside risk because they lack the scale and staying power of their larger competitors.

GoodRx Holdings has delivered a steep 89.7% share price decline over the past five years. The stock has recently bounced, which sits awkwardly with valuation checks that currently lean toward the shares looking expensive rather than clearly mispriced on the downside. The stock is down 89.7% over five years, which suggests long term holders have worn a heavy loss despite the recent short term recovery. Future progress on converting its platform usage into consistent cash generation can...

GoodRx Holdings (GDRX) is back in focus after its Q2 2026 earnings report on 5 August, along with raised full-year revenue guidance and a leadership change that appoints Justin Fengler as Chief Financial Officer. See our latest analysis for GoodRx Holdings. The Q2 earnings update and CFO transition come after a period of sharp share price moves for GoodRx Holdings. The stock has a 90 day share price return of 44.18% and a year to date share price return of 30.55%. However, the 3 year total...

Healthcare tech company GoodRx (NASDAQ:GDRX) reported Q2 CY2026 results beating Wall Street’s revenue expectations, but sales fell by 1.3% year on year to $200.4 million. The company’s full-year revenue guidance of $797.5 million at the midpoint came in 2.8% above analysts’ estimates. Its non-GAAP profit of $0.08 per share was in line with analysts’ consensus estimates.

GoodRx (GDRX) CEO & president Wendy Barnes joins Josh Lipton on Market Domination to discuss the company’s strategy to expand beyond prescription savings. Highlighting strong growth across the business, with subscription revenue up 39% and direct-to-pharma sales rising 76% year over year.

Investors can certainly boost their returns by concentrating on stocks trading between $1 and $10. However, a disciplined approach is necessary because many of these businesses are speculative and lack the underlying fundamentals to support their prices.

Moby summary of GoodRx Holdings, Inc.'s Q2 2026 earnings call

Healthcare tech company GoodRx (NASDAQ:GDRX) reported Q2 CY2026 results exceeding the market’s revenue expectations, but sales fell by 1.3% year on year to $200.4 million. The company’s full-year revenue guidance of $797.5 million at the midpoint came in 2.8% above analysts’ estimates. Its non-GAAP profit of $0.08 per share was in line with analysts’ consensus estimates.

SANTA MONICA, Calif., August 05, 2026--GoodRx Holdings, Inc. (Nasdaq: GDRX) ("we," "us," "our," "GoodRx," or the "Company"), the leading platform for medication savings in the U.S., has released its financial results for the second quarter of 2026.